Indeed, previous studies have reported that B-RAF inhibitors, such as dabrafenib, vemurafenib, and sorafenib, that are FDA-approved anti-cancer drugs, can block RIPK3 [30,52]. The gene discussed is RIPK3; the disease is cancer.